ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 514

EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) Is Increased In Sjögren’s Syndrome Patient With Fibromyalgia

Valeria Valim1, Samira T. Miyamoto2, Mauricio Paganotti3, Erica V. Serrano4 and Raquel Altoe4, 1Clínica Médica - Reumatologia, Universidade Federal do Espírito Santo, Vitória, Brazil, 2Educação Integrada em Saúde - Reumatologia, Universidade Federal do Espírito Santo, Vitoria, Brazil, 3Farmacologia, Universidade de Vila Velha, Vitória, Brazil, 4Reumatologia, Universidade Federal do Espírito Santo, Vitória, Brazil

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome and fibromyalgia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjögren's Syndrome: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: The EULAR Sjögren’s Syndrome Patient Reported Index(ESSPRI) is a patient-reported index designed to assess the severity of patients’ symptoms such as dryness, pain and fatigue in primary Sjögren Syndrome (pSS). Considering these symptoms are also very common in fibromyalgia (FM), the association between pSS and FM could contribute to higher scores of ESSPRI. The purpose of this study was to determine if score of ESSPRI differed between pSS patients with and without FM.

Methods: Sixty two women with pSS fulfilling the American–European Consensus Criteria (AECC) were recruited from the Rheumatology Outpatient Clinic of Hospital Universitário Cassiano Antônio de Moraes/Universidade Federal do Espírito Santo (UFES). All were submitted to American College of Rheumatology 1990 Criteria (ACR) for Fibromyalgia and submitted to ESSPRI and EULAR Sjogren’s syndrome Disease Activity Index(ESSDAI). Student’s t-test and Mann-Whitney were used to compare scores of ESSPRI between pSS patients with and without FM (p<0.05) and Pearson’s Correlation was used to correlate score of ESSPRI and ESSDAI (p <0.05).

Results: The mean of age was 49.4 ± 11.6, beginning of symptoms was 7.2 ± 5.4 years and diagnostic time was 3.0 ± 3.3 years. Sixty eight percent were non-Caucasian and 32% Caucasian. ESSPRI mean was 6.87 ± 1.97 and ESSDAI mean was 4.95 ± 6.73, indicating low activity. There was no correlation between ESSDAI score and ESSPRI score (r=0.051; p<0.696). The frequency of fibromyalgia in pSS patients was 43.5%. Stratified analysis showed that pSS patients with FM have higher score of ESSPRI than those without FM (7.35 ± 1.69 vs. 6.17 ± 2.34, p=0.028) (Table 1).

Conclusion: Fibromyalgia is a common comorbidity in pSS patients and it could raise the ESSPRI score and also could explain part of no correlation between ESSPRI and ESSDAI.

Table 1 – Descriptive statistics and score of ESSPRI between primary Sjögren Syndrome patients with and without Fibromyalgia

ESSPRI

Fibromyalgia

Median

Mean

Standard deviation

p-value

Dryness**

 Yes

7.00

7.00

2.62

0.251

No

6.00

6.15

2.92

Fatigue**

 Yes

8.00

7.00

3.32

0.067

No

6.00

5.03

4,07

Pain**

 Yes

8.00

8.04

2.05

0.441

No

8.00

7.33

2.89

Total score*

 Yes

7.67

7.35

1.69

0.028***

No

6.00

6.17

2.34

* Student’s t-test; ** Mann-Whitney test; ***p<0,05


Disclosure:

V. Valim,
None;

S. T. Miyamoto,
None;

M. Paganotti,
None;

E. V. Serrano,
None;

R. Altoe,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/eular-sjogrens-syndrome-patient-reported-index-esspri-is-increased-in-sjogrens-syndrome-patient-with-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology